pharma · Ovarian Cancer · Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer · ANIX
Anixa Biosciences
Anixa Biosciences Inc
Anixa Biosciences is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker ANIX. Primary therapeutic focus areas include Ovarian Cancer, Pathologic Stage IIA-IIIC Triple-Negative Breast Can
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 1982
- Employees
- 12
- Programs
- 2
- Drugs
- 4
- Patents
- 1
Follicle Stimulating Hormone Receptor T Cells
Phase 1 · small molecule · Ovarian Cancer
Follicle Stimulating Hormone Receptor T Cells for Ovarian Cancer is a Phase 1 program (small_molecule) at Anixa Biosciences Inc with 1 ClinicalTrials.gov record(s).
Internal code MCC-21113
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Anixa Biosciences Inc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Ovarian Cancer
- Status
- active
- Trials
- 1